Neurotrope Concludes Data Collection in Confirmatory Phase 2 Clinical Trial of Moderately Severe to Severe Alzheimer's Disease

Stock Information for Neurotrope Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Neurotrope Inc.

Neurotrope Announces Review of Strategic Alternatives to Maximize Shareholder Value
Neurotrope Announces Top-line Results From Confirmatory Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease
Neurotrope Announces Publication Highlighting the Potential of Bryostatin as a Unique Neurorestorative Therapy
Neurotrope Announces Corporate Update and Reports Second Quarter 2019 Financial Results
Neurotrope Strategic Advisory Board Members Participating in Key Opinion Leader Call Sponsored by Oppenheimer's Biotechnology Team
Neurotrope to Present at the Alzheimer's Association International Conference; Neurotrope President and Chief Scientific Officer, Dr. Daniel L. Alkon, to Receive Cure Coin Award; Design of Confirmatory Phase 2 Trial to be Presented
Neurotrope CEO to Present at the Maxim Group Key Opinion Leader Discussion on Alzheimer's Disease on June 26th, 2019
Neurotrope's President and Chief Scientific Officer to Present at the Alzheimer's Solutions Conference at The University of the Sciences in Philadelphia, PA on June 3rd, 2019

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.